

REGULATORY REQUIREMENTS FOR INDs/FIH (FIRST IN HUMAN) STUDIES

SHAYNE COX GAD

Gad Consulting Services, Cary, North Carolina

Contents

- 1 Introduction
- 2 Overview of U.S. Regulations
 - 2.1 Regulations: General Considerations
 - 2.2 Regulations: Human Pharmaceuticals
 - 2.3 Regulations: Environmental Impact
 - 2.4 Regulations: Antibiotics
 - 2.5 Regulations: Biologics
 - 2.6 Regulations Versus Law
- 3 Organizations Regulating Drugs in the United States
- 4 Process of Pharmaceutical Product Development and Approval
- 5 Testing Guidelines
 - 5.1 Toxicity Testing: Traditional Pharmaceuticals
 - 5.2 General or Systematic Toxicity Assessment
 - 5.3 Genetic Toxicity Assessment
 - 5.4 Toxicity Testing: Biotechnology Products
 - 5.5 Toxicity/Safety Testing: Cellular and Gene Therapy Products
- 6 Toxicity Testing: Special Cases
 - 6.1 Oral Contraceptives
 - 6.2 Life-Threatening Disease (Compassionate Use)
 - 6.3 Optical Isomers
 - 6.4 Special Populations: Pediatric and Geriatric Claims
 - 6.5 Orphan Drugs
 - 6.6 Botanical Drug Products
- 7 International Pharmaceutical Regulation and Registration
 - 7.1 International Conference on Harmonization
 - 7.2 Other International Considerations
 - 7.3 Safety Pharmacology

Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing
Edited by Shayne C. Gad
Copyright © 2010 John Wiley & Sons, Inc.